Use of Stem Cell Suspensions containing Separated Fetal Stem Cells in Complex Treatment of Patients with Essential Hypertension
- *Corresponding Author:
- Klunnyk MO
Clinical Department, Cell Therapy Center EmCell
Kyiv City, 37 A Syretska Street, Kyiv 04073
Tel: +38 067 236 27 61 +38 044 223 28 95
Fax: +38 044 468 80 29
E-mail: [email protected]
Received date: October 26, 2016; Accepted date: November 21, 2016; Published date: November 28, 2016
Citation: Klunnyk MO, Sych NS, Matiyashchuk IG, Sinelnyk AA, Ivankova OV, et al. (2016) Use of Stem Cell Suspensions containing Separated Fetal Stem Cells in Complex Treatment of Patients with Essential Hypertension. J Stem Cell Res Ther 6: 366. doi: 10.4172/2157-7633.1000366
Copyright: © 2016 Klunnyk MO, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objective: To study a complex treatment including stem cell preparations with separated Fetal Stem Cells (FSCs) in suspensions and therapy effect on dynamics of arterial blood pressure in the patients with essential arterial hypertension. Material and methods: Comparative study on 25 patients of the main group suffering from essential arterial hypertension was performed to investigate the effect of complex treatment with inclusion of preparations of FSCs in the suspensions containing extracted stem cells of fetal liver, brain and heart along with conventional therapy on a dynamics of ABP ranges in the patients. Control Group included 25 patients with essential arterial hypertension who were compared to the patients in the main group based on all characteristics. The patients were studied before FSCs therapy, over 1, 3 and 6 months after treatment by use of separated FSCs. Results: Increased regulation of vascular tone, better contractile function of the heart and enhanced excretory function of kidneys leading to decrease of Circulating Blood Volume (CBV), Cardiac Output (CO) and Total Peripheral Resistance (TPR) of vessels have been established in the patients. In addition, systolic function of LV myocardium was improved by way of increasing contractile cellular elements within myocardium and/or due to enhanced functional reserves of cardiomyocytes in the recipient. Conclusion: FSCs therapy proved to be safe and highly effective in stabilization of systemic Arterial Blood Pressure (ABP) and contributed to better life quality among the patients with arterial hypertension.